Triple
T19773031
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Ibrance |
E474934
|
entity |
| Predicate | isUsedInCombinationWith |
P4791
|
FINISHED |
| Object | fulvestrant |
—
|
NE NERFINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: fulvestrant | Statement: [Ibrance, isUsedInCombinationWith, fulvestrant]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: fulvestrant Context triple: [Ibrance, isUsedInCombinationWith, fulvestrant]
-
A.
Lethenteron
Lethenteron is a genus of jawless, eel-like lampreys found primarily in freshwater and coastal regions of the Northern Hemisphere.
-
B.
Vitrakvi
Vitrakvi is a targeted cancer therapy (larotrectinib) used to treat solid tumors that have a specific NTRK gene fusion, regardless of the tumor’s location in the body.
-
C.
Ibrance
Ibrance is a targeted oral cancer medication (palbociclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
-
D.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
-
E.
Talycopa
Talycopa is a locality or area within the community of Llansamlet in Swansea, Wales.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: fulvestrant Target entity description: Fulvestrant is an estrogen receptor antagonist used as hormone therapy for certain types of advanced or metastatic breast cancer, often in postmenopausal women.
-
A.
Lethenteron
Lethenteron is a genus of jawless, eel-like lampreys found primarily in freshwater and coastal regions of the Northern Hemisphere.
-
B.
Vitrakvi
Vitrakvi is a targeted cancer therapy (larotrectinib) used to treat solid tumors that have a specific NTRK gene fusion, regardless of the tumor’s location in the body.
-
C.
Ibrance
Ibrance is a targeted oral cancer medication (palbociclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
-
D.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
-
E.
Talycopa
Talycopa is a locality or area within the community of Llansamlet in Swansea, Wales.
- F. None of above. chosen
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d8e51a43a08190956bc6df13c91a77 |
completed | April 10, 2026, 11:55 a.m. |
| NER | Named-entity recognition | batch_69e6535e450c8190a2628245ae0d0bd3 |
completed | April 20, 2026, 4:25 p.m. |
Created at: April 10, 2026, 1:48 p.m.